MDGL (Madrigal Pharmaceuticals) Short-Term Debt to Capital

Corporate company logo of Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals (MDGL) is actively recruiting commercial experts and hepatologists to scale its business. The short-term debt-to-equity trend reflects liability dynamics, where the value of 0.00 describes the current leverage level. Growth is driven by AI molecule screening and line automation, while the retention of core scientists via stock options guarantees the success of breakthrough metabolism drugs.

Ratio of Short-Term Indebtedness to Capital: Madrigal Pharma (MDGL) for 07/04/2022 - 10/31/2026

Analytical breakdowns for Madrigal Pharmaceuticals

- stock quotes and analyst forecast:
Stock Price Madrigal Pharma|MDGL - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Madrigal Pharmaceuticals Inc|MDGL - Enterprise Value
- book capitalization information:
Net Assets per Single Share Madrigal Pharmaceuticals|MDGL - Accounting Value of Company|Market Value to Book Value Ratio madrigalpharma.com|MDGL - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Madrigal Pharmaceuticals|MDGL - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Madrigal Pharmaceuticals, Inc.|MDGL - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Madrigal Pharmaceuticals Inc|MDGL - Company Long-Term Liabilities|Company Short-Term Debts Madrigal Pharmaceuticals|Quick Liquidity Indicator madrigalpharma.com
- company profitability and valuation multiples indicators:
MDGL - Profit After Payment of Taxes
Fundamental valuation:MDGL Madrigal Pharma
Brand item of Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals (MDGL) specializes in developing innovative drugs for the therapy of metabolic liver disorders in the US. This activity requires a precise alignment of current liabilities with the volume of equity. The metric measures the share of loans maturing within one year relative to the company's net assets. Analysis of the short-term debt-to-equity chart allows for an assessment of the business's financial stability and liquidity risk.

Competitors of Madrigal Pharmaceuticals

Short-Term Debt to Capital ASND|CORT (Corcept Therapeutics Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital RYTM (Rhythm Pharmaceuticals)|Short-Term Debt to Capital akerotx.com AKRO|MTSR - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital MLTX (MoonLake Immunotherapeutics AG)|Crinetics Pharma (CRNX) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio NewAmsterdam Pharma Corp|SLNO (Soleno Therapeutics) - Short-Term Debt to Capital|Short-Term Debt to Capital amicusrx.com|Short-Term Debt to Equity Ratio ETNB (89bio)|AGIO (Agios) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Structure Pharma GPCR|MDXG - Short-Term Debt to Equity Ratio|Rezolute, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital lexpharma.com|MBX (MBX Biosciences) - Short-Term Debt to Equity Ratio|ALT: Short-Term Loans to Capital Ratio|AARD (Aardvark Therapeutics Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital Sagimet Biosciences Inc|Short-Term Debt to Capital BIOA|Short-Term Debt to Equity BMEA (biomeafusion.com)|Short-Term Debt to Equity Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. (GUTS) - Current Liabilities to Capital|VTVT - Short-Term Debt to Equity|ATPC: Short-Term Debt to Equity|PLUR: Short-Term Debt to Capital|SYBX - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lipocine|Matinas BioPharma Holdings Inc. (MTNB) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Spruce Biosciences (SPRB)|Short-Term Debt to Equity Ratio Galecto Corporation GLTO|Short-Term Debt to Equity Carmell Corporation CTCX|LUMO - Short-Term Debt to Equity Ratio|Organovo - Short-Term Debt to Capital|RDUS - Short-Term Debt to Capital